CSPC Pharmaceutical Group (HK:1093) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CSPC Pharmaceutical Group has renewed lease agreements with CHL and NCP for three years starting January 2025, involving industrial premises in Shijiazhuang, China for drug production. These agreements are categorized as connected transactions under Hong Kong’s Listing Rules, requiring reporting and announcement but exempt from independent shareholder approval. The move indicates CSPC’s strategic alignment with its substantial shareholder’s associates to continue its production activities.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
